News

Los especialistas realizarán una actualización sobre los avances en el tratamiento de los síndromes mielodisplásicos, la mielofibrosis, las terapias específicas para la Leucemia Mieloide Aguda (LMA) o la Leucemia Linfoblástica Aguda (LLA).

Recent studies have sought to demonstrate the effectiveness of new targeted therapies, such as FLT3 or menin inhibitors, and cellular therapy such as CAR-T in ever earlier scenarios

Bone marrow donation, which may improve the patient's prognosis, does not pose any health risk for the donor nor does it require admission to the operating room

Research into acute leukemia is currently one of the most active fields in Spain due to the shortcomings persisting in the treatment of these patients, who amount to more than 6,000 every year¹

Depending on the type of leukemia, patients will have different genetic alterations or mutations that determine the progress of treatment

Better understanding of cell tumor biology opens possibilities for targeted therapies in acute leukemia

It will feature prominent speakers from different countries in America and Europe, as well as the intervention of professionals from the MD Anderson leukemia department in Houston

New drugs, like FLT3 inhibitors, improve survival rates in people with acute myeloid leukemia, acting on altered intracellular signaling pathways that allow cancer cells to grow

This allows patients with lymphoma or multiple myeloma who require a hematopoietic stem cell transplant to return to their center of origin to continue their own post-transplant care

Madrid, December 10, 2020 - Dr. Karla Vallejo, from Hospital del Mar, in Barcelona; Dr. Alejandro Avendaño, from the Hospital Universitario Clinico of Salamanca, and Dr. Diego Conde, from the Hospital Universitario Príncipe de Asturias in Alcala de Henares, Madrid, are the winners of the first edition of “El Reto” (‘The Challenge’), an initiative launched by MD Anderson Cancer Center Madrid – Hospiten on the occasion of the 9th Annual Meeting on Acute Leukemia, held this year online. The winners will receive a scholarship of 3,000 € for their participation in and excellent use of the congress, coordinated by Dr. Adolfo de la Fuente, head of the center's Hematology Service, and Dr. Miguel Angel Sanz, of La Fe University and Polytechnic Hospital in Valencia.